Skip to content
The Policy VaultThe Policy Vault

Stivarga (regorafenib)Medica

Appendiceal cancer

Initial criteria

  • age ≥ 18 years
  • advanced or metastatic disease
  • previously treated with a fluoropyrimidine (e.g., capecitabine, 5-fluorouracil [5-FU])
  • previously treated with oxaliplatin
  • previously treated with irinotecan
  • EITHER (tumor/metastases are RAS wild-type AND patient has tried Erbitux (cetuximab) OR Vectibix (panitumumab) OR tumor did not originate on left side of colon) OR tumor/metastases have RAS mutation (KRAS or NRAS)

Approval duration

1 year